Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells

BACKGROUND: Bortezomib (BZM), alone or in combination with other chemotherapies, has displayed strong anticancer effects in several cancers. The efficacy of the combination of BZM and mitoxantrone (MTX) in treating prostate cancer remains unknown. METHODS: Anticancer effects of combination of BZM an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ying, Liu, Qiuzi, Wei, Wei, Zhang, Guoan, Yan, Siyuan, Dai, Rongrong, Sun, Ying, Su, Dubo, Lv, Shun, Xia, Yong, Li, Jing, Li, Changlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515742/
https://www.ncbi.nlm.nih.gov/pubmed/34645397
http://dx.doi.org/10.1186/s12885-021-08841-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515742/
https://www.ncbi.nlm.nih.gov/pubmed/34645397
http://dx.doi.org/10.1186/s12885-021-08841-1

Ejemplares similares